RCUS
Arcus Biosciences, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +18.2% ·
share flow +30.0% ·
net new positions +15.4%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 83 | +1 | 62.00M | $1.91B | +8 | −7 |
| Q1 2026 | 85 | -2 | 57.45M | $1.24B | +6 | −8 |
| Q4 2025 | 87 | -1 | 64.26M | $1.53B | +1 | −2 |
| Q3 2025 | 20 | +2 | 36.84M | $500.99M | +2 | — |
| Q2 2025 | 15 | -1 | 35.18M | $286.34M | — | −1 |
| Q1 2025 | 13 | +2 | 11.54M | $90.60M | +4 | −2 |
| Q4 2024 | 11 | 0 | 8.18M | $121.86M | +1 | −1 |
| Q3 2024 | 10 | 0 | 4.70M | $71.80M | — | — |
| Q2 2024 | 10 | — | 4.00M | $60.94M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 3.70M | +23.5% | $29.02M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Point72 Asset Management ✦ | 2.87M | +43.6% | $22.51M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.39M | +14.8% | $10.91M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.39M | +14.8% | $10.91M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Millennium Management ✦ | 1.19M | +29.2% | $9.38M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Wellington Management ✦ | 1.08M | New | $8.50M | 0.0% | New | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 1.08M | New | $8.50M | 0.0% | New | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 1.08M | New | $8.50M | 0.0% | New | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 1.08M | New | $8.50M | 0.0% | New | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 1.08M | New | $8.50M | 0.0% | New | 1 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 377.10K | +4.6% | $2.96M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 377.10K | +4.6% | $2.96M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 298.42K | +103.4% | $2.34M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 14 | Renaissance Technologies ✦ | 204.00K | +1002.7% | $1.60M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | Fisher Asset Management ✦ | 137.64K | New | $1.08M | 0.0% | New | 1 | SEC ↗ |
| 16 | Marshall Wace ✦ | 112.05K | New | $879,601 | 0.0% | New | 1 | SEC ↗ |
| 17 | Marshall Wace ✦ | 112.05K | New | $879,601 | 0.0% | New | 1 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 90.95K | +253.9% | $713,989 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 90.95K | +253.9% | $713,989 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 90.95K | +253.9% | $713,989 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 90.95K | +253.9% | $713,989 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 90.95K | +253.9% | $713,989 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 23 | D. E. Shaw & Co. ✦ | 56.04K | New | $439,922 | 0.0% | New | 1 | SEC ↗ |
| 24 | T. Rowe Price ✦ | 34.07K | +10.1% | $268,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Wellington Management | $8.50M | 0.0% |
| Wellington Management | $8.50M | 0.0% |
| Wellington Management | $8.50M | 0.0% |
| Wellington Management | $8.50M | 0.0% |
| Wellington Management | $8.50M | 0.0% |
| Fisher Asset Management | $1.08M | 0.0% |
| Marshall Wace | $879,601 | 0.0% |
| Marshall Wace | $879,601 | 0.0% |
| D. E. Shaw & Co. | $439,922 | 0.0% |
Exited
| Adage Capital Partners | $6.60M | was 0.0% |
| Norges Bank | $506,915 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 209 holders, 119.00M shares, $2.56B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.83K sh · $84,810
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
24.7% of class · View original SEC filing ↗